Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences
Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced a series of milestones including key IDN (Integrated Delivery Network) health system approvals, significant regulatory approval, and published preclinical evidence supporting the continued adoption and global expansion of MagnetOs™, which are going to be presented at the Octavian Seminar 2026 and Baader Bank Swiss Equities Conference 2026.
“These milestones reflect the strength and consistency of our strategy, building durable access through major U.S. health system approvals, achieving one of the most rigorous regulatory certifications globally, and continuing to expand a differentiated evidence portfolio for MagnetOs,” said Chris Fair, Chief Executive Officer of Kuros Biosciences. “Together, these achievements reinforce our position as an evidence driven biologics company and support the continued global adoption of MagnetOs as we execute on our long-term growth objectives.”
Recent U.S. Healthcare System Approvals
Kuros announced that all five MagnetOs formulations have recently received approval across multiple large IDN health systems in the U.S., a critical step for access and adoption at scale.
Health system approvals are typically granted following comprehensive evaluation by multidisciplinary stakeholders including clinical, supply chain, and value analysis teams. Such evaluations generally assess efficacy, safety, clinical performance, economic considerations, and alignment with system-wide standards of care. These approvals will enable expanded surgeon access to MagnetOs across participating facilities, subject to local hospital approval and clinical implementation processes.
“System-level approvals reflect confidence not only in a product’s performance, but in the rigor of the evidence behind it,” said John Griffin, Chief Business Officer of Kuros Biosciences. “These approvals reduce access barriers and position MagnetOs for broader adoption across major U.S. health systems, which will support the company to achieve its financial targets.”
MDR Certification Achieved
Kuros also announced that MagnetOs Granules and MagnetOs Putty received certification under the European Union Medical Device Regulation (MDR), on December 22, 2025. MDR certification is among the most stringent regulatory frameworks globally and is required to maintain market access in the European Union.
Achievement of MDR certification supports the continued commercial availability of MagnetOs in Europe and other international markets and reflects Kuros’ operational and clinical readiness to meet evolving regulatory standards.
“MDR certification represents one of the most rigorous regulatory thresholds globally,” said Philippe Saudan, Senior Vice President, Quality, Regulatory and Clinical of Kuros Biosciences. “We are proud to have achieved MDR certification for MagnetOs, underscoring the strength of our clinical evidence and supporting continued access to this technology for surgeons and patients throughout Europe and other international markets.”
Publication of Head-to-Head Preclinical Sheep PLF Study
Further strengthening the MagnetOs evidence portfolio, a newly published preclinical study in Clinical Spine Surgery evaluated MagnetOs Flex Matrix in a clinically relevant, instrumented sheep posterolateral lumbar fusion (PLF) model and compared its performance head-to-head against commercially available synthetic bone grafts, including a synthetic peptide with anorganic bone mineral in a hydrogel carrier, a synthetic silicate-substituted calcium phosphate in a hydrogel carrier, and a synthetic bioglass in a collagen matrix.*1
At 12 weeks, MagnetOs demonstrated significantly higher fusion rates across multiple endpoints including radiography, micro-CT, biomechanics, and histology. Histological analysis showed 100% bilateral fusion in MagnetOs treated segments, while the synthetic peptide achieved fusion in 33% of segments and both the synthetic silicate-substituted calcium phosphate and synthetic bioglass demonstrated 0% bilateral fusion. Histology further confirmed continuous bridging bone formation and mature lamellar bone integrated directly with MagnetOs.*1
This study reinforces the importance of using animal models with robust multi-endpoint analysis to distinguish true bone fusion from residual graft material, particularly in challenging PLF procedures.2
Together with previously published human biopsy findings, these results further differentiate MagnetOs from competing bone graft technologies and support its long-term positioning as an evidence-driven solution for surgeons seeking reliable fusion outcomes.*1,3
Continued Clinical Evidence Expansion
These milestones build on Kuros’ ongoing clinical development efforts, including the recently announced ASTRA study, a global, prospective, randomized, controlled, multi-center Level I clinical trial evaluating MagnetOs compared to autograft (patient’s own bone) in patients undergoing hindfoot or ankle fusions. ASTRA represents Kuros’ continued investment in high quality clinical evidence across multiple anatomical applications.
Event Calendar
January 15, 2026 – Octavian Seminar 2026, Davos
January 16, 2026 – Baader Bank Swiss Equities Conference 2026, Bad Ragaz
March 10, 2026 – Publication Annual Report 2025
April 14, 2026 – Trading Update Q1-2026
April 15, 2026 – Annual Shareholders’ General Meeting